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Objective: To describe the clinical findings, magnetic resonance imaging features, 13 
management and outcome of canine cases with presumed optic neuritis of non-infectious 14 
origin that were presented to a UK referral centre from January 2000 to December 2015. 15 
Materials and Methods: The clinical database was searched for optic neuritis. Dogs with 16 
acute-onset vision impairment, systemic immunosuppressive treatment and follow-up of ≥6 17 
months were included. Information collected included: age; gender; breed; clinical signs and 18 
duration; physical, ophthalmic and neurological examination findings; concurrent systemic 19 
disease; and results of electroretinogram, magnetic resonance imaging, cerebrospinal fluid 20 
analysis, polymerase chain reaction and serology testing for Toxoplasma gondii, Neospora 21 
caninum and canine distemper virus, haematology and serum biochemistry profiles, 22 
abdominal ultrasound, thoracic radiography, treatment and outcome. 23 
Results: Twenty-eight dogs were included, with a total of 48 affected optic nerves. Age at 24 
presentation ranged from 6 months to 10.5years. Fundoscopic evidence of optic nerve disease 25 
was present in 34 of 48 (71%) optic nerves. Magnetic resonance imaging revealed 26 
enlargement of 32 of 48 (67%) nerves and contrast enhancement of 28 of 48 (58%) nerves. 27 
Cerebrospinal fluid analysis performed in 25 of 28 (89%) dogs revealed pleocytosis (>5 28 
nucleated cells/uL) in 11 of 25 (44%) and increased protein (>0.35g/L) in 11 of 25 (44%). 29 
Immunosuppressive prednisolone was administered to all dogs. Prednisolone was used alone 30 
in 9 of 28 (32%) dogs; the remaining 19 dogs received a combination of prednisolone with 31 
cytosine arabinoside, cyclosporine and/or azathioprine. Vision was recovered in 24 eyes 32 
(50%) of 18 affected dogs.  33 
Clinical significance: A positive response to treatment was observed in 64% of dogs with 34 
presumptively diagnosed optic neuritis treated with immunosuppressive medication.  35 
 36 
Key Words: Canine, optic neuritis, CN II, neuro-ophthalmology, optic nerve. 37 
 38 
INTRODUCTION 39 
The optic nerve (CN II) is formed by the axons of the retinal ganglion cells, whose soma are 40 
found in the innermost part of the retina (Glass & DeLahunta 2009). In dogs, the majority of  41 
the axons within CN II will cross at the level of the optic chiasm to synapse at the lateral 42 
geniculate nuclei or the pretectal nuclei (Glass & DeLahunta 2009). A complete lesion of CN 43 
II causes unilateral vision loss and an afferent deficit in the menace response, dazzle reflex 44 
and pupillary light reflex pathways (Glass & DeLahunta 2009).  45 
Differential diagnoses for acute onset of blindness in dogs include sudden acquired retinal 46 
degeneration syndrome (SARDS) (Montgomery et al. 2008), retinal detachment, glaucoma 47 
(Grozdanic et al. 2007), retrobulbar disease (Mason et al. 2001), optic neuritis (ON) and 48 
tumours affecting the visual pathways (Davidson et al. 1991, Seruca et al. 2010). Less 49 
commonly, conditions such as cerebrovascular ischaemic infarction, head trauma (Gelatt 50 
1974) and metabolic diseases, such as hypertensive or hepatic encephalopathy, 51 
hypoglycaemia or hypoxia (O’Neill et al. 2013, Lidbury et al. 2016), have been described as 52 
causes for acute blindness. For this reason, the use of MRI in conjunction with full physical, 53 
neurologic and ophthalmic examination, cerebrospinal fluid (CSF) analysis and serological 54 
testing are paramount to detection and characterisation of ON in dogs (Armour et al. 2011).  55 
ON is commonly characterised by a sudden onset of blindness with a dilated pupil, secondary 56 
to inflammation of CN II (Bianca & Brooks 2013). Infectious diseases associated with ON in 57 
dogs include: viral (e.g. canine distemper virus (Richards et al. 2011), tick-borne encephalitis 58 
virus (Stadtbaumer et al. 2004), fungal (e.g. cryptococcosis (Jergens et al. 1986), 59 
blastomycosis (Treviño 1966), histoplasmosis (Gwin et al. 1980)) and bacterial infections 60 
(e.g. Ehrlichiosis (Leiva et al. 2005). Other causes of canine ON include traumatic, 61 
nutritional (e.g. Vitamin A deficiency (Fischer & Jones 1972)] and toxic [e.g. closantel 62 
intoxication (McEntee et al. 1995)) aetiologies. Furthermore, ON has also been reported in 63 
association with an extension of sterile inflammatory disease of the central nervous system 64 
(e.g. granulomatous meningoencephalitis [GME]) (O’Neill et al. 2005). In many dogs, this 65 
inflammatory process is deemed idiopathic and is presumed to be immune-mediated on the 66 
basis of clinical response to immunosuppressive treatment (Fischer & Jones 1972).  67 
The aims of this study were to describe the clinical findings, MRI features, management, 68 
outcome and long-term follow- up of canine cases presumptively diagnosed with idiopathic/ 69 
immune-mediated ON.  70 
 71 
MATERIALS AND METHODS 72 
Medical records of all dogs seen in a UK referral centre for evaluation of acute onset of 73 
vision impairment between January 2000 and December 2015 were reviewed. Inclusion 74 
criteria included all canine cases with presumptive diagnoses of ON that underwent complete 75 
physical examination, ophthalmic examination (performed by a veterinary ophthalmologist or 76 
veterinary ophthalmology resident), neurological examination (performed by a veterinary 77 
neurologist or veterinary neurology resident), full haematology and comprehensive serum 78 
biochemistry pro- files, serological titres or polymerase chain reaction testing [per- formed on 79 
blood or CSF] for infectious diseases (Toxoplasma gondii, Neospora caninum, Canine 80 
distemper virus); 1.5T MRI scanner (Signa Echospeed, General Electric, Milwaukee, WI) of 81 
the head; and a minimum of 6 months’ follow-up (either at the referral centre or via telephone 82 
updates with the owner/ referring veterinary surgeon) during which there was no evidence of 83 
progression that would be incompatible with, or call into question, a diagnosis of a primary 84 
inflammatory condition. All MRI studies included fast spin echo T2-weighted sequences 85 
(repetition time [TR] 2200-5420ms; echo time [TE] 80.47– 89.22 ms; slice thickness 2–5 86 
mm) and pre- and post-intravenous injection of contrast medium (gadolinium, Bayer’s 87 
Gadovist® (gadobutrol)) transverse fast spin echo T1-weighted sequences (TR 260–760ms; 88 
TE 9.00–14.00ms; slice thickness 2–5mm). Further sequences were performed at the 89 
imager’s discretion; however, all studies included sequences in transverse, dorsal and sagittal 90 
planes. MRI abnormalities were categorised as absent if no lesions were noticed, isolated ON 91 
(I-ON) if only the optic nerve or nerves showed signs consistent with inflammation and 92 
multi-focal if other areas of the brain exhibited signs consistent with inflammation. Cases 93 
were excluded if there was evidence of pathology involving the visual pathway(s) caudal to 94 
the optic chiasm or within the ocular visual axis that could explain the clinical signs, evidence 95 
of retinal/optic nerve head disease not compatible with ON, evidence of infectious or 96 
neoplastic disease, significant abnormalities on haematology and serum biochemistry 97 
profiles, abnormal electroretinography (ERG) or progression of neuro- logical disease despite 98 
appropriate immunosuppressive treatment (which could bring into question a presumptive 99 
diagnosis of an inflammatory aetiology). Cases considered stable on treatment (i.e. no 100 
improvement but no progression) were not excluded, nor were cases that relapsed with 101 
tapering of therapy.  102 
Patient information collected included: breed, gender and neuter status, age at diagnosis, 103 
clinical signs exhibited at and before presentation, duration of clinical signs, MRI findings, 104 
CSF analysis, treatment administered (medication(s) used, length of treatment, length of 105 
treatment at immunosuppressive doses), recovery of CN II function (recovery of menace 106 
response and pupillary light reflexes) and outcome. Follow-up was performed through a 107 
combination of clinical re-examination at the referral centre, evaluation of post-diagnosis 108 
clinical records and telephone conversations with the owner. For dogs in which the final 109 
clinical re-examination at the referral centre was within 6 months of diagnosis, subsequent 110 
clinical information was collected by telephone conversations with the owner and/or the 111 
referring veterinary surgeon. Visual function was assessed based on the presence or absence 112 
of the menace response and dazzle reflex with intact facial nerve function. A successful 113 
outcome was defined as recovery of visual function in one or both affected eyes and recovery 114 
of menace response and pupillary light reflexes (partial or complete)  115 
 116 
RESULTS 117 
A total of 28 dogs met the inclusion criteria. The individual breeds are shown in Table 1, and 118 
signalment is detailed in Table 2. The majority of dogs were of small breeds (<10 kg; 16/28, 119 
57%), followed by large breeds (>25kg; 9/28, 32%) and medium breeds (10–25kg; 3/28, 120 
11%). Of the 28 dogs, 7 (25%) were entire females, 8 (29%) neutered females, 4 (14%) entire 121 
males and 9 (32%) neutered males. The mean (median; range) age at presentation was 5.9 122 
years (5.8 years; 0.6–10.5 years).  123 
The most frequent clinical signs at the time of presentation were acute onset of visual 124 
impairment (27/28, 96%) and mydriatic pupils (12/28, 43%). Blepharospasm (1/28, 4%) and 125 
exophthalmos (1/28, 4%) were also reported. The menace response and dazzle reflex were 126 
absent in one eye in eight dogs (8/28, 29%) and both eyes in 20 cases (20/28, 71%), giving a 127 
total of 48 affected eyes.  128 
Fundoscopic examination revealed signs consistent with ON in 20 dogs (71%) affecting 34 129 
eyes (71%). The most common signs were peripapillary retinal detachment, optic nerve head 130 
(ONH) inflammation (exudates, haemorrhages), ONH atrophy, hyperpigmentation of the 131 
non-tapetal fundus and white deposits on the non-tapetal fundus (Table 3). ERG was 132 
performed in 17 dogs and was bilaterally normal in all cases (Table 2).  133 
Five dogs (5/28, 18%) presented other neurological signs apart from deficits within the visual 134 
pathway, with two of these dogs displaying two or more additional neurological signs. These 135 
neurological deficits included: proprioceptive deficits in one or more limbs (3/28, 11%), 136 
unilateral facial paresis (1/28, 4%), horizontal nystagmus (1/28, 4%), mild proprioceptive 137 
ataxia of all four limbs (1/28, 4%), decreased facial sensation on one side (1/28, 4%), 138 
hyperaesthesia on palpation over the cranium (1/28, 4%) and moderate pelvic limb ataxia 139 
secondary to previous peripheral vestibular disease (1/28, 4%). Four of this dogs displaying 140 
additional neurological signs presented with fundic lesions suggestive of ON.  141 
MRI changes consistent with ON were seen in most dogs (26/28, 93%). Examples of the MRI 142 
findings are depicted in Fig 1. These included CN II enlargement (32/48 eyes, 67%), contrast 143 
enhancement of the CNII (28/48eyes, 58%), enlargement of the optic chiasm (10/28 dogs, 144 
36%), changes suggestive of encephalitis/meningoencephalitis/meningoencephalomyelitis 145 
(5/28 dogs, 18%), contrast enhancement or thickening of the meninges (4/28 dogs, 14%), 146 
contrast enhancement or T2-weighted hyperintensity within non-nervous tissues adjacent to 147 
the CN II (6/48 eyes, 13%) and CN II atrophy (1/48 eyes, 2%). In three dogs (3/28, 11%), the 148 
CN II changes were the sole finding(s) on MRI. Most dogs (19/28, 68%) demonstrated two or 149 
more concurrent MRI abnormalities in addition to CN II changes, and seven (7/28, 25%) had 150 
only one concurrent MRI abnormality in addition to CN II changes.  151 
Five dogs displaying bilateral signs of blindness showed MRI features suggestive of 152 
inflammation in only one CNII, while the contralateral CNII appeared normal on MRI. All 153 
five dogs presented fundic changes suggestive of ON, bilaterally in three and unilaterally in 154 
two cases. Among this group, ERG was performed and was normal in three dogs. In addition, 155 
a further two bilaterally blind dogs exhibited no MRI abnormalities in either CN II (Table 2). 156 
The presumptive diagnosis of ON in these two cases was based on the presence of fundic 157 
abnormalities (both cases) and the normality of the ERG result in one case (Table 2).  158 
After MRI, CSF was collected from either the cerebellomedullary cistern or via lumbar 159 
puncture in 25 cases (25/28, 89%). For the remaining three cases, MRI findings were 160 
suggestive of increased intracranial pressure, and this procedure was deemed unsafe. CSF 161 
analysis was abnormal in most dogs (15/25, 60%; Table 2). Pleocytosis alone (>5 nucleated 162 
cells/uL) was present in four cases (4/15, 27%) and albuminocytological dissociation (protein 163 
>0.35g/L) in four dogs (4/15, 27%). A combination of pleocytosis and increased protein level 164 
was present in seven dogs (7/15, 47%). The pleocytosis was lymphocytic in four dogs (4/11, 165 
36%), monocytic in four dogs (4/11, 36%), mixed mono- nuclear in three dogs (3/11, 27%) 166 
and neutrophilic in one dog (1/11, 9%).  167 
Treatment  168 
The treatment and follow-up information is detailed in Table 4. The treatment protocol varied 169 
among cases depending on clini- cian preference and experience, owner constraints 170 
(financial, ease of administration, availability of follow-up treatment), patient temperament 171 
and medical history; however, all dogs received immunosuppressive doses of prednisolone. 172 
Prednisolone was used alone in nine dogs (9/28, 32%), and the remaining dogs received a 173 
combination of prednisolone and cytosine arabino- side (7/28, 25%), cyclosporine (4/28, 174 
14%), azathioprine (1/28, 4%), cytosine arabinoside and cyclosporine (3/28, 11%), cytosine 175 
arabinoside and azathioprine (2/28, 7%) or cyclosporine and azathioprine (2/28, 7%).  176 
 177 
Outcome  178 
The combinations of treatment and recovery of vision are summarised in Table 5. A total of 179 
24 affected nerves (24/48, 50%) recovered function in 18 dogs (18/28, 64%). The median 180 
time for recovery of vision was 10.5 days (range 2–60 days) after starting 181 
immunosuppressive treatment.  182 
The median duration of treatment was 365days (56– 2920 days) for the dogs that recovered 183 
vision and 180 days (21–1095 days) for those that did not. The median duration of treatment 184 
at immunosuppressive doses was 20 days (0–210 days) for dogs that recovered vision and 185 
35days (7–1095days) for those that did not.  186 
Dogs that recovered vision exhibited clinical signs for a median duration of 4.5days (1–60 187 
days) before referral, whereas clinical signs were present for a median duration of 7 days (3–188 
35 days) in dogs that did not recover vision. The duration of clinical signs noted by the owner 189 
before referral exceeded 1 week for 2 of the 19 dogs (11%) that recovered vision and 3 of 9 190 
dogs (33%) that did not recover vision. Recovery of vision was more prevalent in neutered 191 
dogs (94% recovered vision) than entire dogs (27% recovered vision).  192 
Five dogs (5/28, 18%) relapsed after tapering the dose of immunosuppressive drugs. 193 
However, four of these dogs (4/5, 80%) again recovered vision after a return to 194 
immunosuppressive doses of medication.  195 
 196 
DISCUSSION 197 
This study presents the retrospective evaluation of a series of canine cases diagnosed with 198 
presumptive idiopathic ON. Idiopathic ON is considered an ocular form of GME. CN II 199 
involvement in GME can occur as part of the disseminated or focal forms or as an entity of its 200 
own (O’Neill et al. 2005). Affected dogs may initially present solely with ophthalmologic 201 
signs but subsequently develop other neurological signs associated with disseminated central 202 
nervous system lesions (O’Neill et al. 2005). In dogs, ON is often deemed idiopathic and 203 
presumed to be immune-mediated (Fischer & Jones 1972), while in humans, ON is most 204 
commonly considered to be idiopathic and may occur alone or in association with other 205 
disease pro- cesses such as demyelinating lesions (multiple sclerosis being the most common 206 
cause), autoimmune disorders and infectious and inflammatory conditions (Hoorbakht & 207 
Bagherkashi 2012).  208 
In the cases presented in this study, the presumptive diagnosis of ON was made based on 209 
complete physical, neurological and ophthalmic examinations; blood tests; ERG (in the 210 
absence of fundic lesions); and MRI and CSF findings consistent with previous  211 
reports (Davidson et al. 2002, O’Neill et al. 2005). In this study, the response to 212 
immunosuppressive treatment and exclusion of other possible causes of ON, with consistent 213 
MRI findings (enlargement and enhancement of the CN II) and an elevation of CSF nucleated 214 
cell count, might indicate the presence of an immune-mediated component. Progression of 215 
clinical signs despite treatment with immunosuppressive agents can indicate an underlying 216 
infectious or neoplastic disorder. Given the difficulty of obtaining an ante-  217 
mortem definitive diagnosis, although it introduced a degree of bias in our population through 218 
exclusion of dogs whose signs progressed, only patients with static or improving signs while 219 
receiving appropriate immunosuppressive treatment were included in the present study to 220 
minimise the risk of misdiagnosis.  221 
Based on the fundoscopic findings, canine ON can be classified as intra-bulbar ON (where 222 
fundic abnormalities are present) and retrobulbar ON (where fundic abnormalities are absent) 223 
(Fischer & Jones 1972). In the present study, most cases presented with fundic lesions such 224 
as peripapillary haemorrhage, retinal detachment, ONH inflammation, ONH atrophy and 225 
hyperpigmentation of the non-tapetal fundus. Similar findings were found in another study, 226 
where ONH swelling and elevation were described in all dogs (n = 50) diagnosed with ON 227 
(Davidson et al. 2002). In another retrospective study (n = 96), fundoscopic findings included 228 
ONH elevation (n = 96), peripapillary retinal oedema or separation (n = 37), retinal 229 
haemorrhage or dilation of retinal vasculature (n = 23) and multiple inflammatory foci in the 230 
peripapillary region (n = 13) (Smith et al. 2017). In contrast to human medicine, in which 231 
retrobulbar ON represents two-thirds of human ON cases (Hoorbakht & Bagherkashi 2012), 232 
retrobulbar ON has been described in only four dogs (Smith et al. 2017). In the eight cases in 233 
the present study with normal ocular fundoscopic examination, the presumed diagnosis of 234 
retrobulbar neuritis was made through the presence of MRI abnormalities such as CN II 235 
enlargement, enlargement of the optic chiasm or contrast enhancement of the ON and normal 236 
ERG.  237 
In the present study, slightly more males than females were affected, and it seemed that 238 
recovery of vision was more likely in neutered than entire dogs. The mean age of dogs with 239 
ON in the present study (5.9years) is similar to the mean age of 6.34years reported in a 240 
previous study (Davidson et al. 2002). The present study showed that more than half of 241 
affected dogs were of small breeds, with the most commonly affected breeds being the Lhasa 242 
Apso and West Highland white terrier. This is similar to reported GME cases, in which 243 
middle-aged small-breed dogs are commonly affected (O’Neill et al. 2005). In contrast, 244 
large-breed dogs were most commonly affected by ON in another study (Smith et al. 2017). 245 
Therefore, further studies are necessary to determine whether a breed predisposition exists.  246 
The increasing use and availability of MRI in veterinary medicine has provided better 247 
contrast resolution for the visualisation of the orbit and CN II (Dennis 2000). Hence, MRI is 248 
the method of choice to evaluate the cranial nerves in companion animals with cranial 249 
neuropathies (Parry & Volk 2011). In this study, MRI allowed excellent depiction of the 250 
anatomy of CN II due to its excellent soft-tissue contrast and better delineation of the entire 251 
visual pathway (Seruca et al. 2010). However, no abnormalities were seen on MRI in two 252 
bilaterally blind dogs. In the first case, CSF analysis was within normal limits, and the second 253 
exhibited slight albuminocytologic dissociation (0.36 g/L). In both these cases, the diagnosis 254 
was made based on abnormalities evident on ophthalmic examination and, in one case, a 255 
normal ERG result. There are only three recent studies published in veterinary literature 256 
regarding ON in which both MRI and CSF were performed. The first (Seruca et al. 2010) 257 
included two cases of ON in association with meningoencephalitis. One dog in that study 258 
exhibited T1- and T2-weighted images and short time inversion recovery hyperintensity and 259 
contrast enhancement of both CN II, with lymphocytic pleocytosis of the CSF (Seruca et al. 260 
2010). However, results of MRI and CSF were unremarkable in the second dog (Seruca et al. 261 
2010). The second study reported that only 2 of 13 dogs demonstrated pathologic CSF 262 
alterations (Armour et al. 2011). The third study included 96 dogs grouped into I-ON, 263 
multifocal meningoencephalitis of unknown origin (MUE), microbial infection, neoplasia, 264 
orbital inflammation and suspected ivermectin toxicosis (Smith et al. 2017). Forty-two cases 265 
were diagnosis with I-ON, with these subdivided into 17 confirmed and 25 unconfirmed 266 
cases. A total of 35 cases were confirmed with MUE. CSF was significantly higher in dogs 267 
with MUE compared with I-ON (Smith et al. 2017). In the current study, CSF analysis was 268 
abnormal in 60% dogs. The CN II are brain tracts rather than nerves per se and, as such, are 269 
sur- rounded by the subarachnoid space that contains CSF (Bianca & Brooks 2013). 270 
Therefore, ON alone may cause some CSF abnormalities. In human medicine, Sanberg & 271 
Bynke (1973) reported pleocytosis in 60% and increased total protein concentrations in 24% 272 
of CSF samples from 25 patients with I-ON.  273 
The correlation between different treatment protocols and recovery of vision or the likelihood 274 
of relapse of clinical signs was not analysed as case numbers within each group were low. 275 
Large prospective studies with standardised treatment protocols are necessary to evaluate 276 
these. Potentially worthy of future investigation may be evaluation of the response to 277 
azathioprine. In our study, this was the only medication with which all treated dogs (4/4) 278 
recovered vision in at least one eye [compared with 7/12 (58%) dogs treated with a protocol 279 
including cytosine arabino- side, 4/8 (50%) dogs treated with a protocol including 280 
cyclosporine and 18/28 (64%) dogs treated with prednisolone alone or in combination with at 281 
least one other immunosuppressive agent]. However, in addition to the very small number of 282 
cases who received azathioprine, it must also be noted that three of these dogs also received a 283 
third immunosuppressive agent. Larger case numbers with standardised treatment protocols 284 
would be necessary to comment further on the efficacy of azathioprine compared with other 285 
immunosuppressive agents.  286 
The median duration of clinical signs before referral was shorter in dogs that recovered vision 287 
compared with those that did not. This may suggest that prompt diagnosis and treatment 288 
could be important in obtaining a successful outcome; however, further studies with greater 289 
case numbers would again be necessary to investigate this further.  290 
Prognosis has generally been considered guarded for recovery of vision in dogs with ON. In 291 
previous studies, 30–33% of dogs diagnosed with ON recovered partial or complete vision 292 
after starting therapy (Davidson et al. 2002, Smith et al. 2017). In contrast, our results 293 
showed a partial or complete recovery of vision in response to treatment in 64% of dogs.  294 
The cases included in our study were presumptively diagnosed with ON. Histopathological 295 
confirmation is required for definitive diagnosis of ON, with reported features including 296 
marked loss of ganglion cells and mild to moderate astrogliosis within the CN II fibre and 297 
ganglion cell layers in the retina (Maehara et al. 2009). However, as obtaining a definitive 298 
diagnosis may require sampling of the affected CN II, the nature of diagnosis alone would 299 
prevent evaluation of the response to treatment. The retrospective nature of the study meant 300 
that exclusion of all other potential aetiologies (such as fungal infection, tick-borne 301 
encephalitis or ehrlichiosis) was not possible, although as these diseases are of low 302 
prevalence in the UK, they were considered very unlikely.  303 
There are many limitations to this study, the majority because it is a retrospective analysis of 304 
a presumptively diagnosed condition and the low number of included cases. Another 305 
limitation is the lack of ERG in 11 cases – however, of the 10 dogs for which no recovery of 306 
vision was reported, 7 were reported to have normal ERG. Therefore, although the potential 307 
for concurrent SARDS cannot be excluded in the remaining three dogs that did not recover 308 
vision, it could be ruled out as a contributing factor in 70% of non-responders. Despite these 309 
limitations, the results obtained potentially indicate a better response to treatment than has 310 
been previously reported – a prospective multi-centre study would assist in confirming this 311 
finding.  312 
This retrospective study provides valuable information for veterinarians regarding the clinical 313 
findings, MRI features, management and outcome of canine cases with presumed ON of non- 314 
infectious origin. The term idiopathic immune-mediated ON is used for cases of ON in which 315 
no aetiologic diagnosis is found and that respond to immunosuppressive therapy. Although 316 
clinical signs and ocular abnormalities may be helpful in reaching a presumptive diagnosis of 317 
ON, this study emphasises the relevance of performing an MRI to identify retrobulbar 318 
involvement and rule out structural lesions (such as tumours) in situations where surgical 319 
biopsy is not possible. A positive response to treatment was observed in 64% of dogs with 320 
presumptively diagnosed ON treated with immunosuppressive medication; however, further 321 
comparative studies are required to demonstrate the safety and effectiveness of this 322 
intervention.  323 
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Firgure 1. All images are at the level of the optic chiasm. (A) Transverse T2-weighted image 403 
depicting bilaterally enlarged optic nerves (arrows), loss of differentiation between the white 404 
and grey matter and flattening of the sulci. (B) Transverse T2-weighted image demonstrating 405 
asymmetry between the right and left optic nerves at the level of the optic chiasm (circled). 406 
(C) Transverse T2-weighted image depicting hyperintensity diffusely affecting the left optic 407 
nerve and extending to the chiasm. (D) Transverse post-contrast T1-weighted image of the 408 
dog depicted in (C), revealing multi-focal areas of contrast enhancement in the left optic 409 
nerve at the level of the optic chiasm. (E and F) Transverse (E) and midline sagittal (F) post-410 
contrast T1-weighted images depicting severe enlargement of the optic chiasm with uniform 411 







Table 1. Breed distribution. 
 Breed Number dogs (%) 
Small breed <10kg Lhasa Apso  4         (14%) 
 West Highland White Terrier  4         (14%) 
 Cavalier King Charles Spaniel 2           (7%) 
 Jack Russell Terrier 2          (7%) 
 Small size crossbreed 2           (7%) 
        Shih Tzu 1           (3%) 
 Bichon Frisé 1           (3%) 
Medium breed 10-25 
kg 
French Bulldog 2           (7%) 
 Springer Spaniel 1           (3%) 
Large breed >25kg Golden Retriever  3         (10%) 
 Labrador Retriever 1           (3%) 
 Airedale Terrier 1           (3%) 
 Boxer 1           (3%) 
 Chow Chow 1          (3%) 
 Greyhound 1           (3%) 
 German Shepherd 1           (3%) 
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1 SB 4y FN 2 Bilateral NP 0 0.17 Multifocal 
2 SB 6y FN Unknown Bilateral Positive NP NP Multifocal 
3 SB 8y MN 14 Bilateral Positive 4 0.29 Multifocal 
4 SB 3y 7m 
FN 
7 Bilateral NP 44 0.47 Multifocal 
5 SB 3y FE 11 Bilateral Positive NP NP Multifocal 
6 SB 6y 5m 
MN 
3 Bilateral NP 34 0.34 Unifocal 
7 SB 6y FE 3 Bilateral NP 32 0.76 Multifocal 
8 SB 10y 1m 
ME 
1 Bilateral Positive 2 0.24 Unifocal 
9 SB 5y 6m 
MN 
5 Bilateral Positive 10 0.41 Multifocal 
10 SB 4y 6m 
MN 
3 Bilateral NP 53 0 Multifocal 
11 MB 5y 4m 
FE 
2 Bilateral Positive NP NP Multifocal 
12 MB 7y 6m 
FN 
3 Bilateral NP 1 0.23 Multifocal 
13 MB 2y 7m 
ME 
3 Bilateral NP NP NP Unifocal 
14 LB 1y 6m 
MN 
1 Bilateral Positive 3 0.28 Absent 
15 LB 3y 2m 
FN 
7 Bilateral NP 5 0.36 Absent 
16 LB 7y MN 7 Bilateral Positive 0 0.21 Unifocal 
17 LB 4y ME 4 Bilateral Positive 3 0.27 Multifocal 
18 LB 6m ME 5 Bilateral NP 49 0.95 Unifocal 
19 LB 10y FN 7 Bilateral Positive 3 0.93 Multifocal 
20 LB 8y 9m 
ME 
14 Bilateral Positive 3 0.64 Multifocal 
21 SB 4y 6m 
FE 
35 Left Positive 1 0.15 Unifocal 
22 SB 8y 9m 
ME 
7 Left NP 14 0.37 Multifocal 
23 SB 4y FN 1 Left Positive 760 1.65 Multifocal 
24 SB 3y 6m 
MN 
6 Left  Positive 23 0.23 Unifocal 
25 LB 10y 5m 
FN 
7 Left Positive 0 0.18 Multifocal 
26 SB 8y 8m 
MN 
4 Right NP 377 0.61 Multifocal 
27 LB 9y 5m 
FN 
60 Right Positive 5 0.44 Multifocal 
28 SB 7y ME 4 Right Positive 11 0.26 Multifocal 
SB Small breed, MB Medium breed, LB Large breed, FE Female entire, FN Female neutered, ME 
Male entire, MN Male neutered, y Year old, NP Electroretinography not performed, Absent no 
signs of inflammation within the optic nerves or central nervous system, I-ON isolated optic 
neuritis; only optic nerve(s) displayed MRI changes consistent with inflammation, Multi-focal 
MRI changes consistent with inflammation were not confined to the optic nerve(s), affecting other 

























(n = 48 eyes) 
ONH swelling  17 (61) 12  (43) 5 (18) 29 (60) 
Peri-ONH retinal 
detachment 
4 (14) 2  (7) 2 (7) 6 (12) 
ONH atrophy 3 (11) 1 (4) 2 (7) 4 (8) 
White deposits 
non-tapetal fundus 
2 (7) 2 (7) 0 2 (4) 
ONH haemorrhage 2 (7) 0 2 (7) 2 (4) 




Table 4.  Treatment, progression and follow-up for dogs with suspected optic neuritis (n = 28). 
Case Immunosuppressive 
drugs used 

















14 120 No Right eye only 
2 Prednisolone, cytosine 
arabinoside, 
cyclosporine 
150 460 No Right eye only 
3 Prednisolone, cytosine 
arabinoside, 
azathioprine 
14 1095 No Left eye only 
4 Prednisolone, 
cyclosporine 
210 719 Yes Complete (bilateral) 
5 Prednisolone, 
cyclosporine 
81 180 Yes No 
6 Prednisolone, cytosine 
arabinoside 
74 2005 No Left eye only 
7 Prednisolone, cytosine 
arabinoside 
1095 1095 No No 
8 Prednisolone, cytosine 
arabinoside 
150 365 No Right eye only 
9 Prednisolone, cytosine 
arabinoside 
90 90 No Right eye only 




7 1550 No Left eye only 
12 Prednisolone, cytosine 
arabinoside, 
azathioprine 
21 561 No Complete  (bilateral) 
13 Prednisolone, cytarabine 
arabinoside, 
cyclosporine 
60 60 No No 
14 Prednisolone 7 425 No Left eye only 
15 Prednisolone 0 70 No Complete (bilateral) 
16 Prednisolone 14 365 No Complete (bilateral) 
17 Prednisolone 7 51 No No 
18 Prednisolone 14 56 No Complete (bilateral) 
19 Prednisolone, cytosine 
arabinoside 
20 180 Yes Left eye only 
20 Prednisolone 14 21 No No 
21 Prednisolone, cytosine 
arabinoside 
54 210 No No 
22 Prednisolone, cytosine 
arabinoside, 
cyclosporine 
35 300 No No 
23 Prednisolone, cytosine 
arabinoside 
53 180 Yes No 
24 Prednisolone 0 2920 No Complete (unilateral) 
25 prednisolone 14 90 No No 
26 Prednisolone, 
cyclosporine 
30 150 No Complete (unilateral) 
27 Prednisolone 44 545 No Complete (unilateral) 
28 Prednisolone, 
cyclosporine 
21 810 No No 
*Length of treatment is determined from the start of immunosuppressive treatment to the termination of 








Table 5. Drug combination and recovery of vision in at least one affected eye (n = 28 
dogs). 
Treatment  Number dogs treated (%) Recovery vision (%) 
PRED (%) only 9/28 (32) 6/9 (67) 
PRED + CYT (%) 
7/28 (25) 5/7 (71) 
P = 1 
PRED + CYCL (%) 
4/28 (14) 2/4 (50) 
P = 0.371 
PRED + AZA (%) 1/28 (4) 1/1 (100) 
P = 0.273 
PRED + CYT + CYCL (%) 3/28 (11) 1/3 (33) 
PRED + CYT + AZA (%) 2/28 (7) 2/2 (100) 
PRED + CYCL + AZA (%) 2/28 (7) 1/2 (50) 
PRED prednisolone, CYT Cytosine arabinoside, CYCL Cyclosporine, AZA 
Azathioprine 
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